Joseph P. Hagan

Joseph P. Hagan is a declared insider at 4 companies (chief executive); the most frequent names are Regulus Therapeutics Inc., Orexigen Therapeutics, Inc. and Aurinia Pharmaceuticals Inc. The record holds 57 filings, for trades running from 27 June 2012 to 25 June 2025.

The open-market side counts 6 purchases for €359k alongside 30 sales for €2.0M. Netting one side against the other leaves €1.6M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 10 share grants and 9 option exercises. 2025 to date brings 1 purchase and 2 sales.

The median purchase comes to €42k. On 3 out of 5 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 27 June 2025, the filings show a transaction in Regulus Therapeutics Inc. The most recent open-market purchase was published on 31 January 2025, 646 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.